{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:03:11Z","timestamp":1761991391637,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007174","name":"Pfizer Inc Boulder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jgar.2021.10.027","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T22:04:50Z","timestamp":1639605890000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials"],"prefix":"10.1016","volume":"28","author":[{"given":"Matthew","family":"Dryden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Leister-Tebbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.10.027_bib0001","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jgo.2018.06.011","article-title":"Current etiology, clinical features and outcomes of bacteremia in older patients with solid tumors","volume":"10","author":"Antonio","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgar.2021.10.027_bib0002","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/clind\/24.4.584","article-title":"The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults","volume":"24","author":"Weinstein","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.027_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12941-017-0214-0","article-title":"Patients with community-acquired bacteremia of unknown origin: clinical characteristics and usefulness of microbiological results for therapeutic issues: a single-center cohort study","volume":"16","author":"Courjon","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2021.10.027_bib0004","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1164\/ajrccm.163.7.9912080","article-title":"Outcomes of primary and catheter-related bacteremia. A cohort and case\u2013control study in critically ill patients","volume":"163","author":"Renaud","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2021.10.027_bib0005","series-title":"StatPearls [Internet]","article-title":"Bacteremia","author":"Smith","year":"2020"},{"key":"10.1016\/j.jgar.2021.10.027_bib0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1590\/S1806-37132012000400003","article-title":"Impact of bacteremia in a cohort of patients with pneumococcal pneumonia","volume":"38","author":"Palma","year":"2012","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.jgar.2021.10.027_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cmi.2019.10.031","article-title":"Burden of bacterial bloodstream infection\u2014a brief update on epidemiology and significance of multidrug-resistant pathogens","volume":"26","author":"Kern","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.10.027_bib0008","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/1469-0691.12144","article-title":"Incidence of bloodstream infection: a review of population-based studies","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.10.027_bib0009","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1586\/14787210.2013.856262","article-title":"Monitoring the epidemiology of bloodstream infections: aims, methods and importance","volume":"11","author":"Sogaard","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2021.10.027_bib0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1469-0691.12195","article-title":"Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe","volume":"19","author":"Goto","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.10.027_bib0011","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/CMR.00002-14","article-title":"Population-based epidemiology and microbiology of community-onset bloodstream infections","volume":"27","author":"Laupland","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.10.027_bib0012","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10096-014-2153-4","article-title":"Developments for improved diagnosis of bacterial bloodstream infections","volume":"33","author":"Loonen","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.027_bib0013","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2018.1413354","article-title":"Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution","volume":"17","author":"Izurieta","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jgar.2021.10.027_bib0014","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jpids\/piaa035","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease after introduction into routine pediatric use","volume":"10","author":"Baxter","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"4","key":"10.1016\/j.jgar.2021.10.027_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004977","article-title":"Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age","author":"Lucero","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jgar.2021.10.027_bib0016","doi-asserted-by":"crossref","first-page":"O630","DOI":"10.1111\/1469-0691.12564","article-title":"Case fatality ratio and mortality rate trends of community-onset Staphylococcus aureus bacteraemia","volume":"20","author":"Tom","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.10.027_bib0017","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2021.10.027_bib0018","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.027_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.027_bib0020","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.suc.2014.08.003","article-title":"Bloodstream infections and central line-associated bloodstream infections","volume":"94","author":"Watson","year":"2014","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.jgar.2021.10.027_bib0021","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.4081\/idr.2017.6849","article-title":"The use of bloodstream infection mortality to measure the impact of antimicrobial stewardship interventions: assessing the evidence","volume":"9","author":"Coulter","year":"2017","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.jgar.2021.10.027_bib0022","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"issue":"Suppl 4","key":"10.1016\/j.jgar.2021.10.027_bib0023","first-page":"iv41","article-title":"CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.jgar.2021.10.027_bib0024","first-page":"iv53","article-title":"CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.10.027_bib0025","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.10.027_bib0026","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.10.027_bib0027","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.10.027_bib0028","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.027_bib0029","unstructured":"Pfizer. Zinforo 600 mg powder for concentrate for solution for infusion: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zinforo-epar-product-information_en.pdf [accessed 12 November 2020]."},{"key":"10.1016\/j.jgar.2021.10.027_bib0030","unstructured":"Allergan. TEFLARO\u2122 (ceftaroline fosamil) injection for intravenous (IV) use. https:\/\/www.allergan.com\/assets\/pdf\/teflaro_pi [accessed 2 December 2020]."},{"key":"10.1016\/j.jgar.2021.10.027_bib0031","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jgar.2021.10.027_bib0032","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ijantimicag.2019.01.016","article-title":"Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: a retrospective dose comparison across three pivotal trials","volume":"53","author":"Corey","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.10.027_bib0033","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/jac\/dkv415","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials","volume":"71","author":"Taboada","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.10.027_bib0034","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3810\/hp.2014.02.1094","article-title":"Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia","volume":"42","author":"Jandourek","year":"2014","journal-title":"Hosp Pract (1995)"},{"key":"10.1016\/j.jgar.2021.10.027_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.027_bib0036","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s15010-019-01304-7","article-title":"Ceftaroline as salvage therapy for complicated MRSA bacteremia: case series and analysis","volume":"47","author":"Bhowmick","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.10.027_bib0037","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.027_bib0038","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"10.1016\/j.jgar.2021.10.027_bib0039","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/INF.0000000000001159","article-title":"A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2021.10.027_bib0040","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000001160","article-title":"A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia","volume":"35","author":"Blumer","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2021.10.027_bib0041","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2021.10.027_bib0042","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jac\/dky519","article-title":"Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h","volume":"74","author":"Cheng","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:49Z","timestamp":1761991189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":42,"alternative-id":["S2213716521002605"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.027","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}